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Abstract
The resolution of inflammation is an integral and natural part of the physiological response to 
tissue injury, infection and allergens or other noxious stimuli. Resolution is now recognised as an 
active process with highly regulated cellular and biochemical events. Recent discoveries have 
highlighted that innate inflammatory cells have bimodal effector functions during the 
inflammatory response, including active roles during the resolution process. Several mediators 
displaying potent pro-resolving actions have recently been uncovered. Lipoxin A4, the lead 
member of this new class of pro-resolving mediators, has anti-inflammatory actions on type 2 
innate lymphoid cells and pro-resolving actions through natural killer cells in asthma 
immunobiology. Eosinophils are also able to control crucial aspects of resolution through the 
generation of pro-resolving mediators. Uncontrolled asthma has been associated with a defect in 
thegeneration of specialised pro-resolving mediators, including lipoxin A4 and protectin D1. Thus, 
bioactive stable analogue mimetics of these mediators that can harness endogenous resolution 
mechanisms for inflammation may offer new therapeutic strategies for asthma and airway 
inflammation associated diseases.
Introduction
Asthma is characterised by increased and chronic airway inflammation, with mucosal 
infiltration of inflammatory cells and release of pro-inflammatory cytokines and lipid 
mediators [1]. The airway inflammation of asthma, which is often allergic by nature, has 
been attributed to ongoing adaptive helper T-cell type-2-mediated inflammation [2]. There is 
increasing evidence that innate immunity plays critical roles in the pathobiology of asthma, 
in chronic stable inflammation and during episodes of exacerbated acute inflammation in 
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response to a variety of stimuli, such as allergen inhalation, exposure to environmental 
pollutants or microbial infection [3].
Most studies have focused on the role of innate inflammatory cells (i.e. eosinophils, mast 
cells, basophils, neutrophils, macrophages, several different subsets of dendritic cells, and 
newly described innate lymphoid cells (ILCs)) along with activated resident structural cells 
(epithelial cells, fibroblasts and airway smooth muscle cells) to accentuate and perpetuate 
the airway inflammation in asthma. Indeed, these cells release a vast array of pro-
inflammatory and potentially tissue destructive compounds (eicosanoids, reactive oxygen 
species, cytokines, chemokines, growth factors and proteases) into the extracellular space 
[4]. Recent discoveries have highlighted that many innate inflammatory cells have bimodal 
effector functions during the inflammatory response, with some having active roles during 
the resolution process.
Resolution of inflammation in asthma is characterised by clearance of inflammatory 
leukocytes from the lung, restoration of epithelial barrier function and dampening of airway 
hyperreactivity [5]. During resolution, multiple specialised mediators and cellular 
mechanisms are enlisted to generate endogenous “braking signals” to restore tissue 
homeostasis [6]. Several classes of counter-regulatory lipid mediators have been recently 
discovered that are generated from polyunsaturated fatty acids (PUFAs) during 
inflammation to promote resolution [7]. These specific pro-resolving lipid mediators are 
produced via biosynthetic circuits engaged during cell–cell interactions between different 
innate immune cells and structural cells at sites of inflammation in the lung and have a large 
array of anti-inflammatory and pro-resolving actions, including on the newly described ILCs 
[8].
In this article, we discuss recent studies on the role of pro-resolving lipid mediators in 
asthma inflammation with a focus on ILCs and eosinophils.
Inflammatory responses and the resolution of inflammation
Acute inflammation is an indispensable host response to insult or tissue injury and is 
initiated within minutes of recognition of a danger signal [9]. The acute inflammatory 
process is characterised by rapid recruitment of granulocytes (i.e. neutrophils, eosinophils 
and basophils) to the inflammatory site, the relative contributions of these cell types are 
dependent on the nature and the location of the inflammatory response. The initial events of 
acute inflammation are coordinated by many pro-inflammatory mediators (i.e. lipid 
mediators such as prostaglandins and leukotrienes, cytokines, and chemokines) that regulate 
vascular permeability and initial recruitment of leukocytes [10].
In health, the acute inflammatory response is generally self-limited, resolving within hours 
or days; however, in many human diseases, including asthma, resolution fails and 
inflammation stalls for a prolonged period. Therefore, failure to adequately resolve acute 
inflammation in asthma may contribute to chronic changes in airway structure and function 
causing clinical expression of asthma symptoms (reviewed in [11]).
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Natural resolution of inflammation is now recognised an active host response. While it is 
driven, in part, by decrements in pro-inflammatory mediators, the promotion of resolution 
involves early signalling pathways engaging biosynthetic circuits for the later formation of 
counter-regulatory mediators [12]. For effective resolution of inflamed tissues to occur 
cessation of the recruitment of granulocytes is required, followed by the recruitment of 
monocytes that differentiate into macrophages, which clear inflammatory cells and tissue 
debris, leading ultimately to the restoration of tissue structure and function [13]. During this 
process, tissue granulocytes undergo apoptosis, a highly regulated cell death mechanism that 
prevents the release of histotoxic cellular contents [14]. Clearance of apoptotic neutrophils 
prompts a switch from a pro-inflammatory to an anti-inflammatory macrophage phenotype, 
which is a prerequisite for macrophage egress via the lymphatic vessels favouring a return to 
tissue homeostasis [15]. Clearance of apoptotic neutrophils also leads to the production of 
additional mediators that suppress the progression of inflammation and promote repair of 
damaged tissues [16, 17].
While several classes of mediators participate in resolution, the enzymatic transformations 
of PUFAs to specific pro-resolving agonists are of particular interest. These PUFA-derived 
mediators display cell-type selective anti-inflammatory, pro-resolving, anti-fibrotic, anti-
angiogenic and anti-infective actions [7, 18].
PUFAs derived pro-resolving mediators
The use of experimental models of acute inflammation that naturally resolve (i.e. self-
limited return to homeostasis) has led to the identification of a novel family of lipid 
mediators generated from PUFAs, named lipoxins, resolvins, protectins and maresins. These 
endogenous counter-regulatory mediators actively stimulate cardinal signs of resolution, 
namely, cessation of leukocytic infiltration, counter-regulation of pro-inflammatory 
mediators, and the uptake of apoptotic neutrophils and cellular debris (reviewed in [7]).
The omega-6 PUFA, arachidonic acid (20:4n-6) is incorporated into cellular phospholipids, 
and upon cell activation, specific phospholipase A2 enzymes release arachidonic acid from 
the sn-2 fatty acyl bond of phospholipids. Arachidonic acid can then be converted 
enzymatically by cyclooxygenase (COX) to prostaglandins, by 5-lipoxygenase (LOX) to 
leukotrienes, or by 5-LOX in collaboration with 12-LOX or 15-LOX to lipoxins [19]. The 
omega-3 PUFAs eicosapentaenoic acid (EPA) (20:5n-3) and docosahexaenoic acid (DHA) 
(22:6n-3) can be enzymatically transformed via LOX pathways to resolvins, protectins and 
maresins (fig. 1) [20–22]. The enzymatic generation of these families occurs primarily via 
transcellular biosynthesis, and in some cases within a single cell-type.
During the acute inflammatory response, the biosynthesis of these resolution-phase 
mediators is initiated during lipid-mediator class switching, in which production of the 
classic initiators of acute inflammation, prostaglandins and leukotrienes, switches to 
specialised pro-resolving mediators as inflammation resolves [23].
These mediators display receptor-mediated cell type specific actions and display potencies 
in the low nanomolar range (table 1).
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Lipoxins
Arachidonic acid-derived lipoxin A4 (LXA4) was the first PUFA-derived mediator found to 
have anti-inflammatory and pro-resolving activities [59]. Lipoxins are derived from the 
sequential actions of LOXs and are principally generated via biosynthetic circuits engaged 
during cell–cell interactions at sites of inflammation. Although lipoxins are present in low 
abundance during the initiation of acute inflammation, their levels increase substantially 
during resolution [23, 60]. In the lung, 15-LOX is a key enzyme for lipoxin generation and 
is expressed by many cells in the inflamed lung, including bronchial epithelial cells, 
macrophages and eosinophils [61–64].
Lipoxins act locally and then are rapidly inactivated by metabolic enzymes via pathways 
shared with other eicosanoids [18, 65]. In addition, lipoxin epimers can be generated in the 
presence of aspirin (acetylsalicylic acid) that are longer acting because of a reduced rate of 
inactivation [26, 66].
LXA4 is an agonist for ALX/FPR2 receptors, which are expressed on both human airway 
epithelial cells and leukocytes [67]. In addition, ALX/FPR2 receptors can be induced by 
specific inflammatory mediators [68]. ALX/FPR2 receptors are also expressed on natural 
killer (NK) cells and type 2 ILCs [31]. In addition to lipoxins signalling through ALX/FPR2, 
these small molecules can act as antagonists at cysteinyl leukotriene receptors and can also 
signal via the aryl hydrocarbon receptor (AHR) [69].
Lipoxins demonstrate cell type-specific actions in vitro relevant to asthma immunobiology 
(table 1). These actions include inhibition of granulocyte locomotion, shape change and 
transmigration, and degranulation and stimulation of monocyte chemotaxis and macrophage 
engulfment of apoptotic neutrophils. In addition to this leukocyte-specific activity, lipoxins 
promote restoration of injured airway epithelium by indirectly blocking the release of the 
pro-inflammatory cytokines interleukin (IL)-6 and IL-8 by the epithelium [39].
EPA and DHA derived pro-resolving mediators
Population surveys report that diets rich in omega-3 fatty acids are associated with lower 
asthma prevalence [70]. Recent studies have identified a new family of pro-resolving lipid 
mediators generated from the omega-3 fatty acids, EPA (20:5n-3) and DHA (22:6n-3) [20]. 
These include the EPA-derived E-series resolvins (RvE1 and RvE2), the DHA-derived D-
series resolvins (RvD1–D6), neuroprotectin/ protectin, and maresin (fig. 1) [71].
Resolvins and protectins bear similaritiy to lipoxins in that their epimers can also be 
generated by the “alternative” acetylated COX-2 pathway in the presence of aspirin, thus 
producing “aspirin-triggered” forms [21].
These mediators, like lipoxins, act as potent anti-inflammatory lipid mediators limiting 
neutrophil influx, and also promote resolution of inflammation by stimulating the clearance 
of apoptotic cells and inflammatory debris by macrophages (table 1) [72]. RvE1 serves as an 
agonist at CMKLR1 receptors [50]. CMKLR1 is expressed on monocytes/macrophages and 
plasmacytoid dendritic cells [73–75]. CMKLR1 is also expressed on NK cells and type 2 
ILCs [31].
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PUFA derived pro-resolving mediators in allergic airway inflammation and asthma
The biological activity of the lipoxins in asthma and allergic disease has been defined over 
the past two decades (table 2). Bioactive, LXA4 stable analogues have been prepared that 
block airway hyperresponsiveness and allergic inflammation in animal models, including 
eosinophil trafficking and tissue accumulation [68, 76]. They also block oedema formation 
and reduce the levels of the pro-inflammatory mediators IL-5, IL-13, CCL11, prostanoids 
and cysteinyl leukotrienes [68]. In humans, LXA4 is generated during asthmatic responses 
[78–80] and, when administered to asthmatic subjects via nebulisation, LXA4 attenuates 
leukotriene C4-induced bronchoconstriction [81].
More severe variants of asthma are associated with diminished lipoxin biosynthesis 
compared with milder asthma [79, 82], suggesting that the chronic inflammatory response in 
asthma may be due, in part, to defective generation of pro-resolving mediators leading to 
inadequate counter-regulation (table 3). Decreased formation of lipoxins in uncontrolled 
asthma has now been identified in distinct populations of adults and children from several 
countries [33, 86, 87, 89]. There is also a decrease in lipoxins in the lungs of patients with 
aspirin-intolerant asthma [83], and exercise-induced asthma compared with the lungs of 
healthy persons [87].
RvE1 is present in the lung [95]. In an experimental model of asthma, RvE1 dampens the 
development and promotes the resolution of allergic airway responses [60, 96, 97]. RvD1 
and aspirin-triggered RvD1also promote resolution of allergic airways responses [54]. 
Protectin D1 (PD1) mediates bronchoprotective actions in a murine experimental model of 
allergic lung inflammation [77] and is decreased in exhaled breath condensates during acute 
exacerbations of asthma [77].
ILCs are newly identified players in asthmatic inflammation and targets for 
specialised pro-resolving mediators
ILCs comprise a newly described family of haematopoietic effectors that play protective 
roles in innate immune responses to infectious microorganisms, lymphoid tissue formation, 
tissue remodelling after damage inflicted by injury or infection, and the homeostasis of 
tissue stromal cells (reviewed in [98]).
NK cells
NK cells are prototypical members of the ILC family. NK cells serve essential roles in host 
defence, including cytokine secretion, contact-dependent cell–cell signalling and direct 
killing of other immune cells, and are involved in combating tumours, viral infections, 
parasites and bacteria [99]. Roles for NK cells in asthma and allergic diseases are undefined 
and both disease-promoting and disease-controlling functions have been suggested [100].
Potential roles for NK cells in resolution of allergic airway responses have been recently 
defined. In a murine model of allergic lung inflammation, NK cells accumulate during 
resolution in the lung draining lymph nodes [97]. Depleting NK cells at the peak of the 
inflammatory response after allergen challenge delays clearance of airway eosinophils and 
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antigen-specific CD4+ T lymphocytes [97]; however, depletion of NK cells before allergen 
challenge has been shown to inhibit airway eosinophilia [101, 102]. Therefore, the timing of 
depletion of NK cells during the allergic inflammatory response may reveal different 
functions of NK cells during inflammation.
Co-culture experiments revealed that human NK cells could induce neutrophil [103] and 
eosinophil apoptosis [31, 104]. Moreover, NK cells from severe asthmatic subjects have a 
reduced capacity to augment eosinophil apoptosis [31]. Apoptosis of inflammatory cells is a 
non-inflammatory mechanism of cell removal and plays a critical role in successful 
resolution of the inflammatory response. Neutrophils and eosinophils can release toxic 
substances and enzymes harmful not only to pathogens, but also to surrounding tissue. In 
asthma, timely regulation of eosinophil activation and apoptosis is probably crucial to avoid 
tissue damage and induce resolution of inflammation [105]. Apoptotic granulocytes can 
subsequently be removed by tissue macrophages before their toxic contents leak out into the 
tissue and result in extensive damage. By accelerating granulocyte apoptosis, NK cells may 
play a role in limiting the inflammatory response and may be involved in the resolution of 
acute inflammation.
It is of interest that NK cells express pro-resolving receptors and that binding to pro-
resolving mediators can modulate NK cell effector functions (fig. 2). NK cells were 
identified to express ALX/FPR2, a receptor for the pro-resolving mediator LXA4, and NK 
cells from subjects with severe asthma have increased ALX/FPR2 expression [31]. LXA4 
can inhibit in a dose-dependent fashion the cytotoxic activity of human NK cells against 
K562 target cells assayed in vitro [106]. Moreover, when NK cells are exposed to LXA4, the 
cells display an increase in NK cell-mediated apoptosis of both eosinophils and neutrophils 
[31]. NK cells also express CMKLR1 (Chemokine-like receptor 1), also known as 
ChemR23 (Chemerin Receptor 23) [31, 107], a receptor for the pro-resolving mediator 
RvE1. RvE1 has been shown to be a potent pro-resolving mediator for allergic airway 
inflammation [60]. In a murine model of allergic lung inflammation, NK cell depletion 
markedly impaired RvE1’s protective actions [97]. Moreover, RvE1 regulates NK cell 
cytotoxicity in vitro [97].
Type 2 ILCs
In addition to NK cells, the ILC family also includes type 2 ILCs (ILC2s). ILCs have similar 
morphologies to T-cells but do not express T- or B-cell antigen receptors or markers of other 
lineages. They are involved in responses to helminth infection and murine models of allergic 
lung inflammation, and can respond to the epithelial-derived cytokines IL-25 (also known as 
IL-17E), IL-33 and thymic stromal lymphopoietin. In an antigen-independent manner, 
ILC2s can generate the cytokines IL-5 and IL-13 that were previously linked to T-helper 
type 2 (Th2) lymphocytes. ILC2s were recently identified in humans as a population of
Lin− cells expressing IL-7R, CRTH2 (a chemoattractant receptor for prostaglandin D2 that is 
also expressed on Th2 cells), and the common NK cell marker CD161 [108].
ILC2s are instrumental in several models of experimental asthma where they significantly 
contribute to the production of IL-5 and IL-13, and to AHR development (fig. 2) [109–114]. 
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ILC2s are present in the blood of asthmatic patients [31]. Human ILC2s express the pro-
resolving receptors ALX/FPR2, and LXA4 prevents prostaglandin D2-stimulated release of 
IL-13 from ILC2s.
In some cases, ILC2 can help restore lung-tissue homeostasis after influenza infection in a 
murine model. In a study by Monticelli et al. [115] following influenza virus infection, ILC2 
depletion led to impaired lung function and tissue repair, along with increased permeability 
of the lung epithelial barrier. It was shown that ILC2s produce a factor from the epidermal 
growth factor family linked to tissue remodelling and repair in asthma, known as 
amphiregulin. Administration of amphiregulin restored epithelial cell integrity, airway 
remodelling, and lung function [115]. In line with these findings, the IL-33–ILC2–IL-13 
axis has been reported to mediate tissue repair functions in a mouse model of biliary injury 
by promoting epithelial restoration [116].
Thus, ILC2 may both promote inflammatory lung disease and also restore airway epithelial 
cell integrity after injury. While these two functions of ILC2s may appear contradictory, the 
homeostatic versus the pathological role of ILCs may be similar to the contrasting roles of 
several other immune cell types. The context in which ILC2s function may determine 
whether the cells are beneficial (enhancing epithelial cell integrity) or detrimental (causing 
airway inflammation and airway hyperresponsiveness). ILCs may have evolved to respond 
rapidly during viral infections and when activated in the absence of appropriate regulation, 
ILC2s may cause disease, such as airway inflammation and AHR.
Emerging roles of eosinophils and eosinophil-derived pro-resolving lipid mediators in 
asthma
Eosinophils are associated with the pathogenesis of asthma, and their accumulation in the 
lungs is often regarded as a defining feature of allergic asthma in humans and in animal 
models [117]. It is assumed that eosinophils are recruited to the lungs by Th2 cells as end-
stage effector cells, because of their ability to secrete a wide array of cytotoxic and pro-
inflammatory mediators. For example, eosinophils can serve as major effector cells inducing 
tissue damage and dysfunction by releasing an array of cytotoxic granule cationic proteins 
including major basic protein, eosinophil cationic protein and eosinophil-derived neurotoxin 
(fig. 3) [118]. Nevertheless, the role of eosinophils in specific features of asthma has been 
controversial in several experimental and clinical studies [119–121]. Recent work showed 
that eosinophils are also able to contribute to the resolution of acute inflammation. In a 
murine model of self-limited zymosan-induced peritonitis, 12/15-LOX-expressing 
eosinophils were recruited to the inflamed loci during the resolution phase of the acute 
inflammatory response and were shown to generate pro-resolving lipid mediators, including 
PD1 [122]. In this nonallergen model, eosinophil-derived PD1 was shown to induce 
macrophage activity to clear apoptotic neutrophils from the site of inflammation. 
Eosinophils can also promote resolution in murine zymosan-induced inflammation by 
regulating the expression of macrophage CXCL13 through the control of the 12/15-LOX-
derived mediator, LXA4 [123].
Interestingly, in a murine model of allergic lung inflammation, PD1, administered before 
aeroallergen challenge, reduced airway inflammation and dampened airway 
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hyperresponsiveness [77]. In addition, in this study levels of PD1 were significantly lower in 
exhaled breath condensates from subjects with asthma exacerbations when compared with 
healthy subjects. PD1 has been confirmed as one of the main anti-inflammatory and pro-
resolving molecules synthesised by human eosinophils [94]. PD1 is an autacoid regulator of 
eosinophils, and suppresses in nanomolar concentrations eosinophil chemotaxis induced by 
CCL11/eotaxin-1 or 5-oxo-eicosatetraenoic acid and modulates the expression of the 
adhesion molecules CD11b and L-selectin; although it has no significant effects on 
eosinophil degranulation, superoxide anion generation or survival (fig. 3). When compared 
with the cells harvested from healthy subjects, biosynthesis of PD1 is decreased in severe 
asthma [94].
Eosinophils are also able to convert 18-hydroperoxyeicosapentaenoic acid (HEPE) into 
17,18-diHEPE, known as RvE3, via the 12/15-LOX pathway [52]. RvE3 displays potent 
anti-inflammatory activity by blocking PMN infiltration in acute peritonitis (fig. 3) [52].
The role of eosinophils in the resolution of inflammation probably extends beyond 
production of pro-resolving lipid mediators and includes pathways resulting from 
interactions with other pro-inflammatory and resident cells in the lung. Recent work showed 
that eosinophils are able to contribute to the resolution of lung-allergic responses following 
repeated allergen challenge in a murine model by producing IL-10, a potent anti-
inflammatory cytokine [124]. In vitro, eosinophils have the potential to polarise 
macrophages through IL-4/13 release to an M2 phenotype, the precursor to resolution 
macrophages (i.e. increased phagocytic activity and production of resolving lipid mediators) 
[125, 126]. Eosinophils were also shown to promote alternatively activated macrophages in 
other disease models (fig. 3) [127, 128].
Therapeutic implications
For asthma, currently available anti-inflammatory agents or therapies under development 
(e.g. glucocorticoids and the biological therapeutics anti-IgE, IL-5 or IL-13) target pro-
inflammatory mediator pathways [129]. While this strategy has been beneficial in some 
clinical conditions, long-term use of corticosteroids can be associated with significant side-
effects and there remain substantial unmet clinical needs [130].
Anti-inflammation and pro-resolution are not synonymous. The definitions of these terms 
have important differences. Although anti-leukocyte actions are commonly considered anti-
inflammatory, it is important to view the role of each cell type in this dynamic process of 
catabasis. Inhibition of neutrophil transmigration and activation is anti-inflammatory but can 
lead to immunosuppression that increases the host’s susceptibility to infection. By contrast, 
restitution of barrier integrity (endothelial, epithelial, or both); recruitment of monocytoid 
cells; and promotion of macrophage clearance of apoptotic cells, microbes and tissue debris 
are all pro-resolving responses, increasing host defence [8, 22]. Therefore, the identification 
of such endogenous anti-inflammatory and/or pro-resolution mechanisms is of wide interest.
Rather than blocking early or select pro-inflammatory mediators, an alternative therapeutic 
strategy might emphasise mimetics of lipoxins, resolvins, protectins, maresins or other 
natural counter-regulatory molecules that accelerate resolution of inflammation. 
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Metabolically stable analogues of some of these compounds have been developed and 
display potent in vivo protective actions in several asthma model systems (table 2). 
Moreover, more severe variants of asthma are associated with diminished lipoxin 
biosynthesis compared with milder asthma (table 3) [79, 82], suggesting that the chronic 
inflammatory response in asthma may be due, in part, to defective generation of pro-
resolving mediators leading to inadequate counter-regulation. Exogenous administration of 
this mediator may benefit these patients by inhibiting and resolving inflammation.
In a recent clinical study, a LXA4-based compound was tested for the topical treatment of 
infantile eczema [131]. Albeit in a small number of patients, the drug reduced the severity of 
eczema to a similar extent as steroid therapy in a double-blind placebo-controlled setting. 
No studies, to date, have been published examining the therapeutic effect of LXA4 in 
asthma.
Conclusion
The resolution of inflammation is integral to the physiological response to tissue injury, 
infection and allergens or other noxious stimuli. Resolution is an active process with highly 
regulated cellular and biochemical events that are engaged to restore tissue function in 
health. Recent discoveries have highlighted that innate inflammatory cells have bimodal 
effector functions during the inflammatory response, including active roles during the 
resolution process. Several mediators displaying potent pro-resolving actions have recently 
been uncovered. LXA4, the lead member of this new class of pro-resolving mediators, has 
anti-inflammatory actions on ILC2 and pro-resolving actions through NK cells in asthma 
immunobiology. Eosinophils are also able to control crucial aspects of resolution through 
the generation of pro-resolving mediators. Uncontrolled asthma has been linked to a defect 
in the generation of specialised pro-resolving mediators, including LXA4 and PD1. Thus, 
bioactive stable analogue mimetics of these mediators that can harness endogenous 
resolution mechanisms for inflammation may offer new therapeutic strategies for asthma 
and airway inflammation associated diseases.
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FIGURE 1. 
Formation of bioactive lipid mediators. Specific pro-resolving lipid mediators are 
enzymatically derived from host essential polyunsaturated fatty acids (PUFAs), including a) 
the omega-6 PUFA arachidonic acid (AA) (C20:4n-6), and b) the omega-3 PUFAs 
eicosapentaenoic acid (EPA) (C20:5n-3) and docosahexaenoic acid (DHA) (C22:6n-3) via 
lipoxygenase (LOX) pathways. AA also forms a range of pro-inflammatory mediators, such 
as prostaglandins (PGs) via cyclooxygenase (COX)-2, and the leukotrienes (LTs) via 
multiple LOX actions.
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FIGURE 2. 
Key functions of innate lymphoid cells in resolution of inflammation in asthma. a) Natural 
killer (NK) cells and b) type 2 innate lymphoid cells (ILC2s) express the pro-resolving 
receptors ALX/FPR2 for lipoxin A4 (LXA4) and CMKLR1 (Chemokine-like receptor 1) for 
resolvin E1 (RvE1). LXA4 inhibits NK cell cytotoxicity and increases eosinophil-induced 
apoptosis by NK cells, and inhibits interleukin (IL)-13 release by ILC2s. RvE1 increases 
airway eosinophilia and antigen (Ag)-specific CD4+ T-cell clearance.
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FIGURE 3. 
Key functions of eosinophils (Eo) in resolution of inflammation in asthma. Eosinophils 
secrete a wide array of cytotoxic and pro-inflammatory mediators. In addition, eosinophils 
may contribute to resolution of inflammation in asthma by producing pro-resolving lipid 
mediators (PD1 and RvE3), by secreting interleukin (IL)-10 and by promoting alternative 
macrophage activation in an IL-4 and IL-13 dependent manner. PMN: polymorphonuclear 
leukocyte; PD1: protectin D1; RvE3: resolvin E3; EPA: eicosapentaenoic acid; DHA: 
docosahexaenoic acid; LOX: lipoxygenase.
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TABLE 1
Cellular actions of specialised pro-resolving lipid mediators in innate immunity relevant to asthma
Mediator Target cell Action(s) References
Lipoxin A4 Eosinophil Inhibits migration and chemotaxis [24, 25]
Inhibits generation of eotaxin and IL-5
Neutrophil Inhibit chemotaxis [26–30]
Inhibit trans-endothelial and trans-epithelial migration
Inhibit neutrophil–epithelial cell interactions
Inhibit superoxide anion generation
Inhibit degranulation
NK cell Inhibits NK cell cytotoxicity [31, 32]
Increases granulocyte induced apoptosis
ILC2 Inhibits IL-13 release [31]
Monocyte Stimulates chemotaxis and adhesion [33–35]
Inhibits peroxynitrite generation
Reduces IL-8 release by cells from individuals with asthma
Macrophage Increases engulfment of apoptotic neutrophils [36, 37]
Dendritic cell Inhibits IL-12 production [38]
Epithelial cell Increases proliferation after acid injury [39, 40]
Inhibits cytokine release
Increases intracellular Ca2+
Endothelial cell Stimulates protein kinase-dependent prostacyclin formation [41–43]
Blocks the generation of reactive oxygen species
Inhibits VEGF-induced endothelial-cell migration
Fibroblast Inhibits IL-1β-induced IL-6, IL-8 and MMP3 production [44, 45]
Inhibits CTGF-induced proliferation
Smooth muscle Inhibits LTC4-initiated migration [46]
Bronchial epithelial cell Stimulates basal cell proliferation after acid injury [39]
Blocks IL-6 and IL-8 release
Resolvin E1 Neutrophil Inhibits trans-epithelial and trans-endothelial migration [47, 48]
Inhibition of superoxide generation
Macrophage Stimulates nonphlogistic phagocytosis of apoptotic neutrophils [49]
Dendritic cell Inhibits IL-12 production [50, 51]
Inhibits migration
Resolvin E3 Neutrophil Inhibits infiltration [52]
Resolvin D1 Neutrophil Inhibits transmigration [53]
Macrophage Inhibits LPS-induced TNF release [54, 55]
Promotes phagocytosis of antigen
Protectin D1 Neutrophil Inhibits TNF-α and IFN-γ release [56–58]
Inhibits PMN transmigration
Upregulates CCR5 expression
Macrophage Stimulates nonphlogistic phagocytosis of apoptotic neutrophils [49]
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IL: interleukin; NK: natural killer; ILC2: type 2 innate lymphoid cell; VEGF: vascular endothelial growth factor; MMP3: matrix metalloproteinase 
3; CTGF: connective tissue growth factor; LTC4: leukotriene C4; LPS: lipopolysaccharide; TNF: tumor necrosis factor; IFN-γ: interferon-γ; PMN: 
polymorphonuclear leukocyte; CCR5: CC-chemokine receptor 5.
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TABLE 2
Biological activities of pro-resolving lipid mediators in asthma and allergic disease models
Mediator Action References
Lipoxins Inhibits airway hyperresponsiveness and pulmonary inflammation [68, 76]
Resolvin E1 Reduces airway inflammation; stimulates LXA4 production; and reduces SRS-A [60]
Resolvin D1 Inhibits airway hyperresponsiveness and pulmonary inflammation [54]
Protectin D1 Protects from lung damage, airway inflammation and airway hyperresponsiveness [77]
LXA4: lipoxin A4; SRS-A: slow-reacting substance of anaphylaxis.
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TABLE 3
Defects of pro-resolving mediators in asthma
Mediator Population References
Lipoxin A4 (LXA4) Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics Adults [83]
Higher urinary aspirin-triggered lipoxin levels in aspirin-tolerant asthma than in aspirin-
intolerant asthma
Adults [84]
Diminished lipoxin biosynthesis in severe asthma Adults [82]
LXA4 defect in induced sputum in severe asthma Adults [33]
Severe asthma is associated with a loss of LXA4 in induced sputum Adults [80]
LXA4 generation is decreased in aspirin-sensitive patients in nasal lavage after aspirin 
nasal challenge
Adults [85]
LXA4 levels in asthma show a relationship with disease severity and aspirin sensitivity Adults [86]
Airway LXA4 generation and LXA4 receptor expression are decreased in severe asthma Adults [79]
The role of LXA4 in exercise-induced bronchoconstriction in asthma Adults [87]
LXA4 biosynthesis is decreased in severe asthma alveolar macrophages Adults [88]
Reversed changes of LXA4 and leukotrienes in children with asthma of different severity 
degree
Children [89]
LXA4 is decreased in the EBC of children recovering from status asthmaticus Children [90]
LXA4 levels are lower in severe asthma and correlate negatively to lung function Adults [91]
LXA4 levels in EBC are lower in moderate-to-severe asthma than in mild asthma Adults [92]
Decreased levels of LXA4 in wheezy infants (blood) Children [93]
Protectin D1 (PD1) PD1 is diminished in EBC from subjects with asthma exacerbation Adults [77]
Impaired PD1 production in eosinophils from subjects with severe asthma Adults [94]
EBC: exhaled breath condensate.
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